165 related articles for article (PubMed ID: 32676326)
1. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS
Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326
[TBL] [Abstract][Full Text] [Related]
2. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
3. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
4. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
6. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma].
Zhao C; Fei KL; Wan R; Song LP; Xiang PC; Duan JC
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):445-451. PubMed ID: 37188631
[No Abstract] [Full Text] [Related]
8. Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?
Guo X; Lin L; Zhu J
J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048614
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma.
Kim RY; Mitra N; Bagley SJ; Marmarelis ME; Haas AR; Rendle KA; Vachani A
JTO Clin Res Rep; 2021 Jun; 2(6):100188. PubMed ID: 34590032
[TBL] [Abstract][Full Text] [Related]
10. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
11. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Hashimoto K; Ozasa H; Yoshizawa A; Yoshida H; Ogimoto T; Hosoya K; Yamazoe M; Ajimizu H; Funazo T; Yoshida H; Sakamori Y; Hirai T
Oncol Lett; 2022 Nov; 24(5):402. PubMed ID: 36276492
[TBL] [Abstract][Full Text] [Related]
15. Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity.
Brcic L; Mathilakathu A; Walter RFH; Wessolly M; Mairinger E; Beckert H; Kreidt D; Steinborn J; Hager T; Christoph DC; Kollmeier J; Mairinger T; Wohlschlaeger J; Schmid KW; Borchert S; Mairinger FD
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917061
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
Gill RR; Umeoka S; Mamata H; Tilleman TR; Stanwell P; Woodhams R; Padera RF; Sugarbaker DJ; Hatabu H
AJR Am J Roentgenol; 2010 Aug; 195(2):W125-30. PubMed ID: 20651171
[TBL] [Abstract][Full Text] [Related]
17. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
18. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of histological subtyping of malignant pleural mesothelioma.
Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
[TBL] [Abstract][Full Text] [Related]
20. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
